Venture Map · Round
Amadix — Series B · €532K
Announced 2020-10-27 · Valladolid · Healthtech
Capital increase of €532,000 in which CDTI, through its Innvierte co-investment programme, invested €252,000 alongside the CRB Bio II fund managed by CRB Inverbío. The money was to finish the European clinical validation of the Colofast colorectal cancer test and bring it to market during 2021.
RoundSeries B
Amount€532K
LeadCRB Inverbío
Date2020-10-27
CityValladolid
SectorHealthtech
